Practitioner's Docket No. MPI00-133M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Liao, Sha-Mei, et al

Application No.:

09/697898

Group No.:

1652

Filed:

October 27, 2000

Examiner:

Prouty, R.

For:

MEKK-1 MOLECULES AND USES THEREOF

Commissioner for Patents Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT TRANSMITTAL

- Transmitted herewith for this application is/are: 1.
 - This Response to Restriction Requirement Transmittal (2 pages) (in duplicate); and
 - Restriction Requirement Response (2 pages). b.

STATUS

2.	Applicant is other than a small entity.	
		R 37 C.F.R. SECTIONS 1.8(a) and 1.10*
I hereby	certify that, on the date shown below, this corresp	condence is being:
0		MAILING in an envelope addressed to the Assistant Commissioner for Patents, 37 C.F.R. SECTION 1.10* as "Express Mail Post Office to Address" Mailing Label No
X		RANSMISSION
Date: <u>1</u>	0 October 2002	Jeffrey L. Kopacz (type or print name of person certifying)

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442. (Page 1 of 2)

Practiti ner's Docket No. MPI00-133M

FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668.

10 October 2002

MILLENNIUM PHARMACEUTICALS, INC.

Theodore R. Allen

Registration No. 41,578

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6815

Facsimile - 617-551-8820

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Chief, Washington, DC 20231. Washington, DC 20231.

Certificate of Transmission under 37 CFR 1.8

FAX RECEIVED OCI 1 1 1002 GROUP 1600

OFFICIAL

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on October 10, 2002.

Jeffrey L. Kopacz

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Response to Restriction Requirement Response to Restriction Requirement Transmittal (2 pages)

(2 pages: 4 pages in

duplicate)

Total

(6 pages)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Practitioner's Docket No. MPI00-133M

This paper is being filed timely. No extensions of time are required. In the event any extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

10 October 2002

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC.

Theodore R. Allen

Registration No. 41,578

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6815 Facsimile - 617-551-8820 LEGAL DEPT.

Practitioner's Docket No. MPI00-133M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liao, Sha-Mei, et al

Application No.:

09/697898

Group No.:

1652

Filed:

October 27, 2000

Examiner:

Prouty, R.

For:

MEKK-1 MOLECULES AND USES THEREOF

Commissioner for Patents Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Madam:

REMARKS

In response to the Restriction Requirement dated September 10, 2002 (Paper No. 10). Applicants hereby elect Group I (claims 1-8, 14, 20, and 25) drawn to DNA, vectors, host cells, and methods of expression.

Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups II-VII in this or subsequent applications.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*				
I hereby	certify that, on the date shown below, this corresponder	nce is being:		
MAILING deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents,				
	deposited with the United States Postal Service in an e Washington, D.C. 20231. 37 C.F.R. SECTION 1.8(a)	37 C.F.R. SECTION 1.10*		
	with sufficient postage as first class mail.	as "Express Mail Post Office to Address" Mailing Label No		
TRANSMISSION				
図	transmitted by facsimile to the Patent and Trademark	Office. Signature W 3		
Date: 10 October 2002		Jeffrey L. Kopacz (type or print name of person certifying)		

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442. (Page 1 of 2)